MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/0008-5472.can-20-2370
Abstract: This study provides key insights into the potential for using MEKi combined with PARPi and anti-PD-L1 for the treatment of all mutant KRAS tumors. Mutant KRAS tumors are associated with poor outcomes, at least in… read more here.
Keywords: parp; immune checkpoint; resistance; meki ... See more keywords
Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29070379
Abstract: Background: Several studies suggest that patients with KRAS-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, KRAS 12c data suggest specific treatment for improving ORR and… read more here.
Keywords: kras tumors; kras mutant; expression; lung ... See more keywords